OBJECTIVE: To conduct post hoc secondary analysis examining the association between change in physical activity. Measured with self-report and accelerometry, from baseline to 1 and 4 years and cardiovascular disease (CVD) outcomes in the Look AHEAD Trial. RESEARCH DESIGN AND METHODS: Participants were adults with overweight/obesity and type 2 diabetes with physical activity. Data at baseline and year 1 or 4 (n = 1,978). Participants were randomized to diabetes support and education or intensive lifestyle intervention. Measures included accelerometry-measured moderate-to-vigorous physical activity (MVPA), self-reported physical activity, and composite (morbidity and mortality) CVD outcomes. RESULTS: In pooled analyses of all participants, using Cox proportional hazards models, each 100 MET-min/week increase in accelerometry-measured MVPA from baseline to 4 years was associated with decreased risk of the subsequent primary composite outcome of CVD. Results were consistent for changes in total MVPA (hazard ratio 0.97 [95% CI 0.95, 0.99]) and MVPA accumulated in ≥10-min bouts (hazard ratio 0.95 [95% CI 0.91, 0.98]), with a similar pattern for secondary CVD outcomes. Change in accelerometry-measured MVPA at 1 year and self-reported change in physical activity at 1 and 4 years were not associated with CVD outcomes. CONCLUSIONS: Increased accelerometry-measured MVPA from baseline to year 4 is associated with decreased risk of CVD outcomes. This suggests the need for long-term engagement in MVPA to reduce the risk of CVD in adults with overweight/obesity and type 2 diabetes.
OBJECTIVE: To conduct post hoc secondary analysis examining the association between change in physical activity. Measured with self-report and accelerometry, from baseline to 1 and 4 years and cardiovascular disease (CVD) outcomes in the Look AHEAD Trial. RESEARCH DESIGN AND METHODS: Participants were adults with overweight/obesity and type 2 diabetes with physical activity. Data at baseline and year 1 or 4 (n = 1,978). Participants were randomized to diabetes support and education or intensive lifestyle intervention. Measures included accelerometry-measured moderate-to-vigorous physical activity (MVPA), self-reported physical activity, and composite (morbidity and mortality) CVD outcomes. RESULTS: In pooled analyses of all participants, using Cox proportional hazards models, each 100 MET-min/week increase in accelerometry-measured MVPA from baseline to 4 years was associated with decreased risk of the subsequent primary composite outcome of CVD. Results were consistent for changes in total MVPA (hazard ratio 0.97 [95% CI 0.95, 0.99]) and MVPA accumulated in ≥10-min bouts (hazard ratio 0.95 [95% CI 0.91, 0.98]), with a similar pattern for secondary CVD outcomes. Change in accelerometry-measured MVPA at 1 year and self-reported change in physical activity at 1 and 4 years were not associated with CVD outcomes. CONCLUSIONS: Increased accelerometry-measured MVPA from baseline to year 4 is associated with decreased risk of CVD outcomes. This suggests the need for long-term engagement in MVPA to reduce the risk of CVD in adults with overweight/obesity and type 2 diabetes.
Authors: Thomas A Wadden; Delia Smith West; Linda Delahanty; John Jakicic; Jack Rejeski; Don Williamson; Robert I Berkowitz; David E Kelley; Christine Tomchee; James O Hill; Shiriki Kumanyika Journal: Obesity (Silver Spring) Date: 2006-05 Impact factor: 5.002
Authors: John M Jakicic; William E Kraus; Kenneth E Powell; Wayne W Campbell; Kathleen F Janz; Richard P Troiano; Kyle Sprow; Andrea Torres; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: William E Kraus; Kenneth E Powell; William L Haskell; Kathleen F Janz; Wayne W Campbell; John M Jakicic; Richard P Troiano; Kyle Sprow; Andrea Torres; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Edward Gregg; John Jakicic; George Blackburn; Paul Bloomquist; George Bray; Jeanne Clark; Mace Coday; Jeffrey Curtis; Caitlin Egan; Mary Evans; John Foreyt; Gary Foster; Helen Hazuda; James Hill; Edward Horton; Van Hubbard; Robert Jeffery; Karen Johnson; Abbas Kitabchi; William Knowler; Andrea Kriska; Wei Lang; Cora Lewis; Maria Montez; David Nathan; Rebecca Neiberg; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Bruce Redmon; Judith Regensteiner; Jack Rejeski; Paul Ribisl; Monika Safford; Kerry Stewart; Dace Trence; Thomas Wadden; Rena Wing; Susan Yanovski Journal: Lancet Diabetes Endocrinol Date: 2016-08-30 Impact factor: 32.069
Authors: Gary D Miller; John M Jakicic; W Jack Rejeski; Melicia C Whit-Glover; Wei Lang; Michael P Walkup; Mimi L Hodges Journal: Obesity (Silver Spring) Date: 2013-01 Impact factor: 5.002
Authors: John M Jakicic; Caitlin M Egan; Anthony N Fabricatore; Sarah A Gaussoin; Stephen P Glasser; Louise A Hesson; William C Knowler; Wei Lang; Judith G Regensteiner; Paul M Ribisl; Donna H Ryan Journal: Diabetes Care Date: 2012-12-06 Impact factor: 19.112